Business Insider

Rectify Pharma Announces Positive Functional Modulator RTY-694 as Development Candidate for Primary Sclerosing Cholangitis

RTY-694 is a potent, orally active ABCB4/BSEP positive functional modulator (PFM) that improves bile composition and enhances bile flow The differentiated mechanism of a dual-targeted ABCB4/BSEP PFM ...
NBC4 Columbus

Rectify Pharma Presents Translational Data Demonstrating Improvements in Kidney Function and Reductions in Vascular Calcification at ERA 2025

Potent, selective ABCC6-targeting positive functional modulator (PFM) improved multiple markers of renal function in animal models of chronic kidney disease (CKD) PFM improved inorganic pyrophosphate ...
manilatimes

Rectify Pharmaceuticals Presents New Translational Data at EASL 2026 Supporting RTY-406, its Clinical Candidate for the Treatment of Primary Sclerosing Cholangitis

RTY-406 demonstrates significant improvements in disease relevant endpoints in a mouse model of primary sclerosing cholangitis (PSC) and proof of mechanism in non-human primates RTY-406 is in Phase 1 ...
C&EN

Rectify launches with $100 million to drug ABC transporters

Rectify Pharmaceuticals has launched with $100 million in series A financing to develop drugs that restore the function of ATP-binding cassette (ABC) transporters. ABC transporters are membrane-bound ...
Morningstar

Rectify Pharma Presents Translational Data Demonstrating Improvements in Kidney Function and Reductions in Vascular Calcification at ERA 2025

“These translational results demonstrate that Rectify’s PFM reduces vascular calcification and kidney injury and improves kidney function through enhancement of ABCC6 function,” said Rajesh Devraj, Ph ...